LH

SEC source: 0001127602-24-003889 · form4.xml · derivative · entry 2

Kong Garheng · CIK 0001435183 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,891

Underlying: Common Stock · 944 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 6, 2025.

F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 6, 2025.

F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 98 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.

SEC source: 0001127602-24-003888 · form4.xml · derivative · entry 2

Kliphouse Kirsten Marie · CIK 0001948684 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,891

Underlying: Common Stock · 944 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 6, 2025.

F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 6, 2025.

F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-24-003887 · form4.xml · derivative · entry 2

Gilliland Dwight Gary · CIK 0001603769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,891

Underlying: Common Stock · 944 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 6, 2025.

F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 6, 2025.

F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 98 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.

SEC source: 0001127602-24-003886 · form4.xml · derivative · entry 2

Davis Jeffrey A. · CIK 0001648477 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,891

Underlying: Common Stock · 944 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 6, 2025.

F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 6, 2025.

F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 98 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.

SEC source: 0001127602-24-003885 · form4.xml · derivative · entry 3

BELINGARD JEAN-LUC · CIK 0001200845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,183

Underlying: Common Stock · 236 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units vest fully on February 6, 2025.

F3 · derivative.expiration_date: The Restricted Stock Units vest fully on February 6, 2025.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 98 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.

SEC source: 0001127602-24-003884 · form4.xml · derivative · entry 4

ANDERSON KERRII B · CIK 0001227159 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,891

Underlying: Common Stock · 944 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 6, 2025.

F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 6, 2025.

F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 98 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.

SEC source: 0001127602-24-003542 · form4.xml · nonDerivative · entry 3

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,636.979

F4 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · balance_after: Amount includes 32.2815 shares acquired on December 29, 2023 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan.

SEC source: 0001127602-24-003580 · form4.xml · derivative · entry 3

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,727

Underlying: Common Stock · 131 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested.

F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-24-003580 · form4.xml · nonDerivative · entry 2

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,173.2194

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-24-003580 · form4.xml · nonDerivative · entry 1

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,218.2194

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-24-003577 · form4.xml · derivative · entry 3

Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,850

Underlying: Common Stock · 246 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested.

F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 92 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.

SEC source: 0001127602-24-003577 · form4.xml · nonDerivative · entry 2

Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,800

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-24-003577 · form4.xml · nonDerivative · entry 1

Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,880

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-24-003555 · form4.xml · derivative · entry 3

BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,404

Underlying: Common Stock · 331 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested.

F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 150 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.

SEC source: 0001127602-24-003555 · form4.xml · nonDerivative · entry 2

BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,120

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-24-003555 · form4.xml · nonDerivative · entry 1

BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,209

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-24-003551 · form4.xml · derivative · entry 3

Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,387

Underlying: Common Stock · 495 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F4 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested.

F4 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested.

F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 253 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.

SEC source: 0001127602-24-003551 · form4.xml · nonDerivative · entry 2

Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,626.0428

F3 · kind: Stock withholding to satisfy tax withholding obligations.

F2 · balance_after: Amount includes 66.4341 shares acquired on May 31, 2023 and 44.8463 shares acquired on December 29, 2023 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan.

SEC source: 0001127602-24-003551 · form4.xml · nonDerivative · entry 1

Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,792.0428

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2 · balance_after: Amount includes 66.4341 shares acquired on May 31, 2023 and 44.8463 shares acquired on December 29, 2023 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan.

SEC source: 0001127602-24-003550 · form4.xml · derivative · entry 3

Schechter Adam H · CIK 0001376841 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,111

Underlying: Common Stock · 3,094 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested.

F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 1,364 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.

SEC source: 0001127602-24-003550 · form4.xml · nonDerivative · entry 2

Schechter Adam H · CIK 0001376841 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,160

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-24-003550 · form4.xml · nonDerivative · entry 1

Schechter Adam H · CIK 0001376841 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,982

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-24-003548 · form4.xml · derivative · entry 3

DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,560

Underlying: Common Stock · 246 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units vested on February 2, 2024.

F3 · derivative.expiration_date: The Restricted Stock Units vested on February 2, 2024.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-24-003548 · form4.xml · nonDerivative · entry 2

DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,515.5491

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-24-003548 · form4.xml · nonDerivative · entry 1

DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,600.5491

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-24-003546 · form4.xml · derivative · entry 3

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,531

Underlying: Common Stock · 856 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested.

F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 1,430 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.

SEC source: 0001127602-24-003546 · form4.xml · nonDerivative · entry 2

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,804

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-24-003546 · form4.xml · nonDerivative · entry 1

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,032

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-24-003545 · form4.xml · derivative · entry 3

Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,543

Underlying: Common Stock · 495 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F4 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested.

F4 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested.

F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 269 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.

SEC source: 0001127602-24-003545 · form4.xml · nonDerivative · entry 2

Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,121.1426

F3 · kind: Stock withholding to satisfy tax withholding obligations.

F2 · balance_after: Amount includes 70.7404 shares acquired on May 31, 2023 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan.

SEC source: 0001127602-24-003545 · form4.xml · nonDerivative · entry 1

Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,253.1426

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2 · balance_after: Amount includes 70.7404 shares acquired on May 31, 2023 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan.

SEC source: 0001127602-24-003542 · form4.xml · derivative · entry 4

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,865

Underlying: Common Stock · 264 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F5 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested.

F5 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested.

F6 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 155 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.

SEC source: 0001127602-24-003542 · form4.xml · nonDerivative · entry 2

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,829.979

F3 · kind: Stock withholding to satisfy tax withholding obligations.

F2 · balance_after: Amount includes 32.2815 shares acquired on December 29, 2023 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan.

SEC source: 0001127602-24-003542 · form4.xml · nonDerivative · entry 1

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,900.979

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2 · balance_after: Amount includes 32.2815 shares acquired on December 29, 2023 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan.

SEC source: 0001127602-23-029890 · form4.xml · derivative · entry 3

DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,806

Underlying: Common Stock · 64 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in two equal annual installments beginning on December 15, 2023.

F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in two equal annual installments beginning on December 15, 2023.

F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 170 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.

SEC source: 0001127602-23-029890 · form4.xml · nonDerivative · entry 2

DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,354.5491

F3 · kind: Stock withholding to satisfy tax withholding obligations.

F2 · balance_after: Amount includes 19.4137 shares acquired on May 31, 2023 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan.

SEC source: 0001127602-23-029890 · form4.xml · nonDerivative · entry 1

DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,373.5491

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2 · balance_after: Amount includes 19.4137 shares acquired on May 31, 2023 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan.

SEC source: 0001127602-23-027956 · form4.xml · nonDerivative · entry 1

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,087.2194

SEC source: 0001127602-23-025848 · form4.xml · derivative · entry 2

Kliphouse Kirsten Marie · CIK 0001948684 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 947

Underlying: Common Stock · 372 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2 · derivative.exercise_date: The Restricted Stock Units vested fully on October 12, 2023.

F2 · derivative.expiration_date: The Restricted Stock Units vested fully on October 12, 2023.

F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 137 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.

SEC source: 0001127602-23-025848 · form4.xml · nonDerivative · entry 1

Kliphouse Kirsten Marie · CIK 0001948684 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 372

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-23-022267 · form4.xml · nonDerivative · entry 1

ANDERSON KERRII B · CIK 0001227159 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,275

SEC source: 0001127602-23-021959 · form4.xml · derivative · entry 3

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,858

Underlying: Common Stock · 56 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on August 1, 2021 and are now fully vested.

F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on August 1, 2021 and are now fully vested.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 63 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.

SEC source: 0001127602-23-021959 · form4.xml · nonDerivative · entry 2

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,471.2194

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-23-021959 · form4.xml · nonDerivative · entry 1

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,488.2194

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-23-020299 · form4.xml · derivative · entry 1

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,974

Underlying: Common Stock · 6,207 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2 · derivative.exercise_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA.

F2 · derivative.expiration_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA.

F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-23-020298 · form4.xml · derivative · entry 1

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,851

Underlying: Common Stock · 3,104 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2 · derivative.exercise_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA.

F2 · derivative.expiration_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA.

F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-23-020297 · form4.xml · derivative · entry 1

Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,004

Underlying: Common Stock · 5,824 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2 · derivative.exercise_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA.

F2 · derivative.expiration_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA.

F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-23-020296 · form4.xml · derivative · entry 1

Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,769

Underlying: Common Stock · 11,648 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2 · derivative.exercise_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA.

F2 · derivative.expiration_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA.

F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-23-020295 · form4.xml · derivative · entry 1

Schechter Adam H · CIK 0001376841 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,841

Underlying: Common Stock · 73,013 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2 · derivative.exercise_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA.

F2 · derivative.expiration_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA.

F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-23-020294 · form4.xml · derivative · entry 1

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,957

Underlying: Common Stock · 20,193 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2 · derivative.exercise_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA.

F2 · derivative.expiration_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA.

F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.